MICC: A Potential Drug Target and Biomarker (G100129192)

Target Name: MICC

NCBI ID: G100129192

MICC

Other Name(s): PERB11.3 | MHC class I polypeptide-related sequence C (pseudogene)

MICC: A Potential Drug Target and Biomarker

Mesothelin (MES) is a transmembrane glycoprotein that is expressed in various tissues, including epithelial, muscular, and connective tissue cells. It is one of the most widely expressed proteins in the human body, and its extracellular domain has been implicated in various cellular processes, including cell adhesion, migration, and invasion. MICC is a unique glycoprotein that is expressed in the mesothelium, which is the lining of the abdominal cavity and the surrounding tissues. It is composed of four distinct domains: an N-terminus, a transmembrane domain, a cytoplasmic domain, and a C-terminus.

The N-terminus of MICC is a glycophosphorylated domain that is known as N-mucin. This domain is rich in basic amino acids, including Asp, Asn, and Asp, which are involved in the formation of MICC dimers. The N-terminus also has a single glycophosphorylated residue, which is known as Asp-219.

The transmembrane domain of MICC is a 21-kDa protein that is composed of four beta-strands that are involved in the formation of a transmembrane network. The transmembrane domain is also rich in basic amino acids, including Asp, Asn, and Asp, which are involved in the formation of MICC dimers.

The cytoplasmic domain of MICC is a 12-kDa protein that is involved in the interaction between MICC and various cellular signaling pathways. The cytoplasmic domain is also rich in basic amino acids, including Asp, Asn, and Asp, which are involved in the formation of MICC dimers.

The C-terminus of MICC is a 16-kDa protein that is involved in the interaction between MICC and various cellular signaling pathways. The C-terminus is also rich in basic amino acids, including Asp, Asn, and Asp, which are involved in the formation of MICC dimers.

MICC has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. It is involved in the formation of tight junctions, which are responsible for maintaining the integrity of the intercellular space and for cell-cell communication. MICC is also involved in the formation of cell pairs, which are essential for the development and maintenance of tissues and organs.

In addition to its role in cellular processes, MICC has also been shown to be a potential drug target. The N-terminus of MICC is rich in basic amino acids, including Asp, Asn, and Asp, which are involved in the formation of MICC dimers. This suggests that MICC may be a good candidate for small molecule inhibitors that can modulate the activity of these proteins.

Furthermore, MICC has also been shown to be a potential biomarker for various diseases, including cancer. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that MICC may be a useful biomarker for the diagnosis and prognosis of these diseases.

In conclusion, MICC is a unique and highly conserved protein that is expressed in various tissues

Protein Name: MHC Class I Polypeptide-related Sequence C (pseudogene)

The "MICC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MICC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets